Imatron turns in disappointing results

Article

South San Francisco ultrafast CT developer Imatron last month reported less than stellar results for 1998 (end-December). The company saw revenues of $30.7 million from the sale of 15 scanners, down 18% compared with last year’s $37.3 million on

South San Francisco ultrafast CT developer Imatron last month reported less than stellar results for 1998 (end-December). The company saw revenues of $30.7 million from the sale of 15 scanners, down 18% compared with last year’s $37.3 million on sales of 18 scanners. Imatron posted a net loss of $14.8 million, compared with a net loss of $11.4 million the previous year.

The firm’s results were affected by the continuing financial turmoil in Asia, traditionally a strong market for ultrafast CT. Imatron was also hit by its inability to sell ultrafast CT scanners itself in the U.S. and Europe during the first quarter of 1998 because Siemens was its exclusive distributor during that period. The company did best in the U.S., where it sold nine of the 15 scanners for the year.

In other Imatron news, an Associated Press article published on March 27 cited research claiming that conventional mechanical CT scanners with electrocardiogram gating can detect coronary calcification just as well as Imatron’s electron beam CT systems. The research was presented at a medical conference in Orlando, FL, sponsored by the American Heart Association, and was covered in several other sources, including The New York Times.

In addition, the company this month formed an alliance with its Japanese distributor, Imatron-Japan, and Japanese general trading company Marubeni to market Ultrafast CT in the Japanese market. Marubeni will provide capital to finance purchases of the scanners and has already assisted in two sales.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.